Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness.
Animals
Dopamine
/ metabolism
Dopamine Agonists
/ pharmacology
Ductus Arteriosus
/ drug effects
Ductus Arteriosus, Patent
/ drug therapy
Female
Fenoldopam
/ pharmacology
Indomethacin
/ toxicity
Mice
Oxygen
/ toxicity
Pregnancy
Receptors, Dopamine D1
/ agonists
Signal Transduction
Vasoconstriction
/ drug effects
Vasodilation
/ drug effects
Vasodilator Agents
/ pharmacology
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
24
06
2019
accepted:
23
11
2019
revised:
19
11
2019
pubmed:
10
12
2019
medline:
1
6
2021
entrez:
10
12
2019
Statut:
ppublish
Résumé
Indomethacin treatment for patent ductus arteriosus (PDA) is associated with acute kidney injury (AKI). Fenoldopam, a dopamine (DA) DA DA receptor expression in CD-1 mouse vessels was analyzed by qPCR and immunohistochemistry. Concentration-response curves were established using pressure myography. Pretreatment with SCH23390 (DA DA DA receptors are present in the ductus but have limited physiologic effects. DA-induced ductus vasoconstriction is mediated via α-adrenergic pathways. The absence of DA
Sections du résumé
BACKGROUND
Indomethacin treatment for patent ductus arteriosus (PDA) is associated with acute kidney injury (AKI). Fenoldopam, a dopamine (DA) DA
METHODS
DA receptor expression in CD-1 mouse vessels was analyzed by qPCR and immunohistochemistry. Concentration-response curves were established using pressure myography. Pretreatment with SCH23390 (DA
RESULTS
DA
CONCLUSION(S)
DA receptors are present in the ductus but have limited physiologic effects. DA-induced ductus vasoconstriction is mediated via α-adrenergic pathways. The absence of DA
Identifiants
pubmed: 31816622
doi: 10.1038/s41390-019-0716-x
pii: 10.1038/s41390-019-0716-x
pmc: PMC7196482
mid: NIHMS1544972
doi:
Substances chimiques
Dopamine Agonists
0
Drd1 protein, mouse
0
Receptors, Dopamine D1
0
Vasodilator Agents
0
Fenoldopam
INU8H2KAWG
Oxygen
S88TT14065
Dopamine
VTD58H1Z2X
Indomethacin
XXE1CET956
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
991-997Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL109199
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128386
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK113073
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL132805
Pays : United States
Références
Gillam-Krakauer, M. & Reese, J. Diagnosis and management of patent ductus arteriosus. Neoreviews 19, e394–e402 (2018).
doi: 10.1542/neo.19-7-e394
Clyman, R. I. et al. PDA-TOLERATE Trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J. Pediatr. 205, 41–48.e46 (2019).
doi: 10.1016/j.jpeds.2018.09.012
Shaffer, C. L. et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit. Care Med. 30, 343–348 (2002).
doi: 10.1097/00003246-200202000-00013
Lee, J. et al. Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics 112, 345–350 (2003).
doi: 10.1542/peds.112.2.345
Barrington K. J., Brion L. P. Dopamine versus no treatment to prevent renal dysfunction in indomethacin‐treated preterm newborn infants. Cochrane Database Syst. Rev. 2002, CD003213. https://doi.org/10.1002/14651858.CD003213 .
Costello, J. M. et al. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr. Crit. Care Med. 7, 28–33 (2006).
doi: 10.1097/01.PCC.0000194046.47306.FB
Zangrillo, A. et al. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. J. Cardiothorac. Vasc. Anesth. 26, 407–413 (2012).
doi: 10.1053/j.jvca.2012.01.038
Segar, J. L., Smith, F. G., Guillery, E. N., Jose, P. A. & Robillard, J. E. Ontogeny of renal response to specific dopamine DA1-receptor stimulation in sheep. Am. J. Physiol. 263, R868–R873 (1992).
pubmed: 1357989
Hooper, C. W. et al. Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero. Am. J. Physiol. Heart Circ. Physiol. 311, H572–H581 (2016).
doi: 10.1152/ajpheart.00822.2015
Reese, J. et al. Regulation of the fetal mouse ductus arteriosus is dependent on interaction of nitric oxide and COX enzymes in the ductal wall. Prostaglandins Other Lipid Mediat. 88, 89–96 (2009).
doi: 10.1016/j.prostaglandins.2008.11.001
Cotton, R. B. et al. Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism. J. Mol. Cell Cardiol. 59, 86–94 (2013).
doi: 10.1016/j.yjmcc.2013.02.010
Pfaltzgraff, E. R. et al. Embryonic domains of the aorta derived from diverse origins exhibit distinct properties that converge into a common phenotype in the adult. J. Mol. Cell Cardiol. 69, 88–96 (2014).
doi: 10.1016/j.yjmcc.2014.01.016
Shelton, E. L. et al. Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone. Physiol. Genomics 46, 457–466 (2014).
doi: 10.1152/physiolgenomics.00171.2013
Vucovich, M. M. et al. Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA. Am. J. Physiol. Heart Circ. Physiol. 307, H732–H740 (2014).
doi: 10.1152/ajpheart.00838.2013
Bucolo, C., Leggio, G. M., Drago, F. & Salomone Dopamine outside the brain: the eye, cardiovascular system and endocrine pancreas. Pharmacol. Therapeutics 9, 107392 (2019).
doi: 10.1016/j.pharmthera.2019.07.003
Shepperson, N. B., Duval, N. & Langer, S. Z. Dopamine decreases mesenteric blood flow in the anaesthetised dog through the stimulation of postsynaptic alpha 2-adrenoceptors. Eur. J. Pharm. 81, 627–635 (1982).
doi: 10.1016/0014-2999(82)90352-1
Hughes, A. D. & Sever, P. S. The action of dopamine and vascular dopamine (DA1) receptor agonists on human isolated subcutaneous and omental small arteries. Br. J. Pharm. 97, 950–956 (1989).
doi: 10.1111/j.1476-5381.1989.tb12036.x
Kohli, J. D., Glock, D. & Goldberg, L. I. Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog. J. Cardiovasc. Pharm. 11, 123–126 (1988).
doi: 10.1097/00005344-198801000-00018
Stoller, J. Z., Demauro, S. B., Dagle, J. M. & Reese, J. Current perspectives on pathobiology of the ductus arteriosus. J. Clin. Exp. Cardiol. 8, S8–001 (2012).
Hsieh, E. M. et al. Medication use in the neonatal intensive care unit. Am. J. Perinatol. 31, 811–821 (2014).
doi: 10.1055/s-0033-1361933
Seri, I., Tulassay, T., Kiszel, J. & Csomor, S. The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus. Int. J. Pediatr. Nephrol. 5, 209–214 (1984).
pubmed: 6397454
Johnston, A. J. et al. Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients. Intensive Care Med. 30, 45–50 (2004).
doi: 10.1007/s00134-003-2032-4
Chen, J. X. et al. Isoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus. Pediatr. Res. 72, 122–128 (2012).
doi: 10.1038/pr.2012.58
Hung, Y.-C., Yeh, J.-L. & Hsu, J.-H. Molecular mechanisms for regulating postnatal ductus arteriosus closure. Int. J. Mol. Sci. 19, E1861 (2018).
doi: 10.3390/ijms19071861
Liet, J. M. et al. Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus. J. Pediatr. 140, 373–375 (2002).
doi: 10.1067/mpd.2002.123100
Fajardo, C. A., Whyte, R. K. & Steele, B. T. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. J. Pediatr. 121, 771–775 (1992).
doi: 10.1016/S0022-3476(05)81914-6
Beaulieu, J. M., Espinoza, S. & Gainetdinov, R. R. Dopamine receptors—IUPHAR Review 13. Br. J. Pharm. 172, 1–23 (2015).
doi: 10.1111/bph.12906
Hughes, A. D. & Sever, P. S. Action of fenoldopam, a selective dopamine (DA1) receptor agonist, on isolated human arteries. Blood Vessels 26, 119–127 (1989).
pubmed: 2474340
Lokhandwala, M. F. & Barrett, R. J. Dopamine receptor agonists in cardiovascular therapy. Drug Dev. Res. 3, 299–310 (1983).
doi: 10.1002/ddr.430030402
Kim, M. O. et al. Localization of dopamine D1 and D2 receptor mRNAs in the rat systemic and pulmonary vasculatures. Mol. Cells 9, 417–421 (1999).
pubmed: 10515606
Amenta, F. et al. Localization of dopamine receptor subtypes in systemic arteries. Clin. Exp. Hypertens. 22, 277–288 (2000).
doi: 10.1081/CEH-100100077
Lappe, R. W., Todt, J. A. & Wendt, R. L. Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J. Pharm. Exp. Ther. 236, 187–191 (1986).
Hammer, G. B., Verghese, S. T., Drover, D. R., Yaster, M. & Tobin, J. R. Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control in pediatric patients. BMC Anesthesiol. 8, 6 (2008).
doi: 10.1186/1471-2253-8-6
Sato, N. et al. The vasodilatory effects of hydralazine, nicardipine, nitroglycerin, and fenoldopam in the human umbilical artery. Anesth. Analg. 96, 539–544 (2003).
pubmed: 12538209
Taylor, A. A. et al. Activation of peripheral dopamine presynaptic receptors lowers blood pressure and heart rate in dogs. Hypertension 5, 226–234 (1983).
doi: 10.1161/01.HYP.5.2.226
Li, X. X. et al. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension 38, 303–308 (2001).
doi: 10.1161/01.HYP.38.3.303
Pyne-Geithman, G. J., Caudell, D. N., Cooper, M., Clark, J. F. & Shutter, L. A. Dopamine D2-receptor-mediated increase in vascular and endothelial NOS activity ameliorates cerebral vasospasm after subarachnoid hemorrhage in vitro. Neurocrit. Care 10, 225–231 (2009).
doi: 10.1007/s12028-008-9143-2
Escano, C. S. et al. Renal dopaminergic defect in C57Bl/6J mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R1660–R1669 (2009).
doi: 10.1152/ajpregu.00147.2009
Jose, P. A. et al. The renal dopamine receptors. J. Am. Soc. Nephrol. 2, 1265–1278 (1992).
pubmed: 1627751
Yoder, S. E. & Yoder, B. A. An evaluation of off-label fenoldopam use in the neonatal intensive care unit. Am. J. Perinatol. 26, 745–750 (2009).
doi: 10.1055/s-0029-1223288